Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer
Abstract
The purpose of this study is to develop a strategy for identifying molecular markers of response of advanced prostate cancer to specific therapies. To achieve this goal we will use clinically relevant prostate cancer patient derived xenografts (PDXs) that are responders and nonresponders (primary and secondary resistance) to therapies that had demonstrated clinical activity. We will identify genomic alterations via integrative genomic analysis of these PDXs. The MD Anderson and Michigan Center for Translational Pathology teams will interact closely to analyze integrative genomic analysis results to generate a responder ID profile hypothesis. The validity of the responder ID profiles will be assessed in clinical trials. We had already identified prostate cancer PDXs responders and non-responders to a therapy that targets fibroblast growth factor receptors pathway. We are now generating tissue samples to perform integrative genomic analysis.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2015
- Accession Number
- AD1003337
Entities
People
- Arul Chinnaiyan
- Nora M. Navone
Organizations
- University of Texas Health Science Center at Houston